我国遴选与转换中成药非处方药概况及思考

doi:10.19803/j.1672-8629.2020.11.08

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (11): 785-789.
DOI: 10.19803/j.1672-8629.2020.11.08

我国遴选与转换中成药非处方药概况及思考

朱兰, 邵波, 夏东胜^*

国家药品监督管理局药品评价中心,北京 100022

收稿日期:2020-11-10 修回日期:2020-11-10 出版日期:2020-11-15 发布日期:2020-11-10
通讯作者: ^*夏东胜,女,主任药师,药品不良反应监测与评价。E-mail: xiadongsheng@cdr-adr.org.cn
作者简介:朱兰,女,主管药师,药品不良反应监测与评价。
基金资助:
国家重点研发计划课题（2018YFC1707409）：中药上市后临床安全性研究指南及药物警戒信息共享系统框架研究

Selection and Switch-to-OTC of Chinese Patent Medicines in China

ZHU Lan, Shao Bo, XIA Dongsheng^*

Center for Drug Reevaluation, CFDA, Beijing 100022, China

Received:2020-11-10 Revised:2020-11-10 Online:2020-11-15 Published:2020-11-10

摘要/Abstract

摘要： 目的通过对我国遴选与转换非处方药中成药部分进行回顾,为新形势下中成药非处方药转换评价提供参考。方法梳理我国处方药和非处方药分类管理相关法规及指导原则,回顾中成药非处方药遴选及转换工作,统计我国中成药非处方品种、通过转换评价品种和转出非处方药目录品种。结果国家药品监督管理局公布的我国遴选与转换非处方药目录中,以药品通用名计,中成药共计3 900余个,包括1999~2004年通过遴选的中成药3 406个,2004~2019年通过转换评价的中成药535个。另外,有25个中成药从非处方药转换为处方药管理。结论中成药非处方药转换评价中,药品上市许可持有人应按照法规及指导原则要求准备资料;转换为非处方药后,药品上市许可持有人应切实做好安全监测,建立有效的药品不良反应收集途径,加强药品不良反应数据分析评价,重视说明书中安全性内容的完善,切实承担起保障患者安全用药的主体责任。

关键词: 处方药和非处方药分类管理, 非处方药, 中成药, 处方药转换为非处方药, 非处方药转换为处方药

Abstract: Objective To review some of the Chinese patent medicines that have been selected or switched to over-the-counter (OTC) products in China so as to provide reference for the switch of prescription drugs to OTC (Rx-to-OTC) drugs in China. Methods Regulations on classification management of prescription and nonprescription drugs and the history of Rx-to-OTC switch were reviewed. Chinese patent medicines which were selected as and switched to OTC drugs were analyzed separately. Results On the basis of the list of generic drugs,there were more than 3 900 OTC Chinese patent medicines,including 3 406 medicines that had been selected as OTC drugs between 1999 and 2004,535 ones that had been switched to OTC,and 25 OTC Chinese patent medicines switched to prescription drugs in the same period. Conclusion The application materials should meet the requirements of regulations on Rx-to-OTC switch applications, After switch to OTC drugs,marketing authorization holders (MAHs) should ensure the safety of these drugs, find effective ways to collect adverse reaction(ADR)reports that should be analyzed to improve the safety instructions of the OTC label. MAHs should be responsible for drug safety for the sake of patients.

Key words: classification management of prescription and non-prescription drugs, OTC, Chinese patent medicines, Rx-to-OTC switch, OTC -to Rx - switch

中图分类号:

R286

朱兰, 邵波, 夏东胜. 我国遴选与转换中成药非处方药概况及思考[J]. 中国药物警戒, 2020, 17(11): 785-789.

ZHU Lan, Shao Bo, XIA Dongsheng. Selection and Switch-to-OTC of Chinese Patent Medicines in China[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 785-789.

参考文献

[1] Tang R,Xia DS,Tian CH,et al.Stage Characteristic of Pprescription and Nonprescription Switch in China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2013,10(5):278-282.
[2] National Medical Products Administration. Provisions of Pprescription and Nonprescription [EB/OL].(1999-06-18)[2020-02-26].http://www.nmpa.gov.cn/WS04/CL2196/323452.html.
[3] National Medical Products Administration. Notice on Evaluation of Pprescription and Nonprescription Switch [EB/OL].(2004-04-07) [2020-02-26].http://www.nmpa.gov.cn/WS04/CL2196/323452.html.
[4] National Medical Products Administration. Notice on Evaluation of Pprescription Switch to Nonprescription [EB/OL].(2010-06-30) [2020-02-26].http://www.nmpa.gov.cn/WS04/CL2196/323778.html.
[5] National Medical Products Administration.Notice on the issuance of 6 guidelines for prescription and Nonprescription Switch [EB/OL]. (2012-11-14)[2020-02-26].http://www.nmpa.gov.cn/WS04/CL2196/323939.html.
[6] Cao MD,Wu Y,Wang Z,et al.Characteristics of Chinese Traditional Patent Medicines Approved for MAarketing in China[J]. Chinese Traditional Ppatent Mmedicine,2019,41(8):1999-2006.
[7] National Medical Products Administration. publication of the non-prescription drugs labels [EB/OL].(2007-02-01)[2020-02-26]. http://www.nmpa.gov.cn/WS04/CL2115/286564.html.
[8] Hang XP,Sun WD,Zhang XP.The Research of OTC Drugs'instructions in China[J].Medicine and Society,2011,24(8):50-52,56.
[9] Wang XF,Wei Q,Luo YJ, et al.Analysis of prescription and non-prescription drug instructions of Chinese patent medicine[J]. Chinese Traditional Ppatent Mmedicine,2019,41(8):2022-2024.
[10] Xia DS,Tian CH,Wang A, et al.The Pprobe into the Necessity of the Safety Monitoring of Over-The-Counter Drug in China[J]. Chinese Journal of Pharmacovigilance,2013,10(2):80-83.
[11] Zheng MJ, Xia DS.Problem Analysis and Suggestion on Application Materials of OTC Switch[J]. Chinese Journal of Pharmacovigilance, 2015,12(10):618-622.
[12] Wang D,Li XL,Dong D, et al.Investigation of Pharmaceutical Manufacturers' Ability of Direct Reporting of Drug Adverse Reactions[J]. Chinese Journal of Pharmacovigilance,2019,16(11): 654-661.
[13] National Medical Products Administration. Annual Report for National ADR Monitoring(2018) [EB/OL].(2019-10-18)[2020-02-26].http://www.nmpa.gov.cn/WS04/CL2138/359373.html.
[14] Hou YF, Liu HL, Zheng MJ.Direct Reporting System for Adverse Drug Reactions Strengthens Fulfillment of Responsibilities of Marketing Authorization Holders[J]. Chinese Journal of Pharmaco vigilance,2019,16(11):662-665.
[15] Xia DS.Discussion on Rational Use of Non-prescription Drugs and Adverse Reactions Avoidance Strategy[J]. Chinese Journal of Pharmacovigilance,2010,7(6):343-346.

我国遴选与转换中成药非处方药概况及思考

Selection and Switch-to-OTC of Chinese Patent Medicines in China

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	雷超, 乔萌, 陈子佳, 张强, 谢雁鸣, 王志飞. 中成药说明书安全性信息项修订的探讨与思考[J]. 中国药物警戒, 2023, 20(12): 1396-1400.
[2]	乔萌, 雷超, 陈子佳, 张强, 王志飞. 含细辛中成药说明书安全项信息现状分析及思考[J]. 中国药物警戒, 2023, 20(12): 1401-1406.
[3]	马冰冰, 张晓朦, 张冰, 林志健, 吕锦涛. 基于文献分析的老年人中成药合理用药与药学服务思考[J]. 中国药物警戒, 2022, 19(6): 595-599.
[4]	张瑞丽, 苏爽, 蒋季明, 张婧. 新癀片致药品不良反应分析[J]. 中国药物警戒, 2022, 19(5): 561-563.
[5]	肖望重, 林聪, 黄莉, 戴冰, 高元峰. 中成药说明书用药禁忌调查分析[J]. 中国药物警戒, 2022, 19(4): 400-403.
[6]	李玲, 刘艳梅, 谭婧, 王雯, 姚明宏, 马玉, 罗小超, 廖星, 刘岩, 宋海波, 温泽淮, 孙鑫. 基于真实世界数据的中成药安全性评价模式构建[J]. 中国药物警戒, 2022, 19(1): 18-22.
[7]	许顺贵, 刘春光. 美国非处方药监管制度浅析与启示[J]. 中国药物警戒, 2021, 18(2): 141-144.
[8]	周莎, 杨洪军, 荆志伟, 李耿. 中药大品种口服中成药说明书安全性信息分析[J]. 中国药物警戒, 2021, 18(10): 981-985.
[9]	田春华, 夏东胜. 借鉴英国制度探讨我国处方药与非处方药“双跨”管理[J]. 中国药物警戒, 2020, 17(12): 883-884.
[10]	王雨,林志健,王笑,褚梦真,张冰. 含补骨脂中成药肝损伤案例的分析与警戒思考[J]. 中国药物警戒, 2018, 15(5): 300-303.
[11]	陈洁烽¹, 刘彤¹, 黄丹萍², 何启迪¹, 陈缵光¹, 姚美村^{1, }. 4种孕妇禁忌中成药对斑马鱼胚胎发育毒性研究[J]. 中国药物警戒, 2017, 14(4): 201-204.
[12]	杨倩, 孙蓉. 抗冠心病中成药临床应用安全警示的归纳与分析[J]. 中国药物警戒, 2016, 13(10): 602-605.
[13]	宋洋, 尤晓敏, 宗毛毛, 杨悦. 我国中药以OTC药品身份在美国上市途径探讨[J]. 中国药物警戒, 2015, 12(9): 547-551.
[14]	王培杰, 王嘉伦, 易智威, 董燕飞, 王璞. 40例喉科非处方中成药不良反应的文献分析[J]. 中国药物警戒, 2015, 12(11): 690-692.
[15]	郑明节, 夏东胜. 非处方药转换申报资料存在的问题分析及建议[J]. 中国药物警戒, 2015, 12(10): 618-622.